Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson’s Disease and Asymptomatic Carriers of Related Genes: A Brief Report
Authors:
- Christos KorosCKChristos Koros
- Athina-Maria SimitsiASAthina-Maria Simitsi
- Anastasia BougeaAnastasia Bougea
- Nikolaos PapagiannakisNikolaos Papagiannakis
- Roubina AntonelouRARoubina Antonelou
- Ioanna PachiIPIoanna Pachi
- Efthalia AngelopoulouEfthalia Angelopoulou
- Andreas PrentakisAPAndreas Prentakis
- Athena ZachouAZAthena Zachou
- Chrysa ChrysovitsanouCCChrysa Chrysovitsanou
- Ion BeratisIBIon Beratis
- Stella FragkiadakiSFStella Fragkiadaki
Open Access
Abstract
Introduction: Previous epidemiological evidence has established the co-occurrence of malignant melanoma (MM) and Parkinson’s disease (PD). Shared molecular mechanisms have been proposed to be implicated in this relationship. The aim of the present study was to assess the prevalence of MM in patients with sporadic and genetic types of PD, as well as in asymptomatic carriers of PD-related genes. Methods: Data regarding past medical history and concomitant disease of 1416 patients with PD (including 20 participants with prodromal disease who phenoconverted to PD), 275 healthy controls (HCs) and 670 asymptomatic carriers of PD-related genes were obtained from the database of the Parkinson’s Progression Markers Initiative (PPMI). Focus was placed on information about a medical record of MM. We also retrieved data regarding the genetic status of selected PPMI participants with a positive MM history. Results: In total, 46 patients with PD reported a positive MM history. Concerning the genetic forms of PD, nine of these PD patients (2.47%) carried a Leucine Rich Repeat Kinase 2 (LRRK2) gene mutation (mainly the G2019S), while eight (4.49%) harbored a Glucocerebrosidase (GBA) gene mutation (mainly the N370S). No alpha-synuclein (SNCA) gene mutation was identified in patients with an MM history. The remaining 29 PD patients (3.5%) were genetically undetermined. In total, 18 asymptomatic carriers of PD-related genes had a positive medical history for MM: among them, 10 carried an LRRK2 gene mutation (2.69%) and 10 a GBA gene mutation (3.51%) (2 were dual carriers). MM history was identified for seven HCs (2.5%). Conclusions: We replicated the previously reported association between genetically undetermined PD (GU-PD) and MM. A correlation of LRRK2 mutations with the development of MM could not be verified in either symptomatic PD patients or asymptomatic carriers, implicating distinct pathogenetic mechanisms as compared to GU-PD. Importantly, despite the limited literature evidence on Gaucher disease, this study highlights for the first time the relatively high prevalence of MM among asymptomatic and symptomatic PD GBA mutation carriers, with potential clinical implications.Keywords
Funding Information
- Michael J. Fox Foundation for Parkinson’s Research funding partners
This publication has 26 references indexed in Scilit:
- Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2Movement Disorders, 2013
- Malignant melanoma in early‐treated Parkinson's disease: The NET‐PD trialMovement Disorders, 2013
- Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literatureBritish Journal of Haematology, 2013
- The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal CellsPLOS ONE, 2012
- The association between Parkinson's disease and melanomaInternational Journal of Cancer, 2011
- High prevalence of malignant melanoma in Israeli patients with Parkinson’s diseaseJournal of Neural Transmission, 2011
- The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutationJournal of Neurology, 2009
- The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patientsAmerican Journal of Hematology, 2009
- Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher DiseaseArchives of internal medicine (1960), 2007
- Malignant melanoma in early Parkinson's disease: The DATATOP trialMovement Disorders, 2007